Results 51 to 60 of about 26,042 (243)

High Shear Stress‐Induced Endothelial Piezo1 Downregulation Promotes Intracranial Aneurysm Formation via the PDGF‐BB/PDGFRβ Paracrine Signaling Pathway

CNS Neuroscience &Therapeutics, Volume 31, Issue 12, December 2025.
HSS downregulates Piezo1 expression in ECs, which subsequently enhances PDGF‐BB expression through the YAP/β‐catenin signaling pathway. The elevated PDGF‐BB facilitates phenotypic transition of VSMCs via PDGFRβ binding, ultimately contributing to IA formation.
Zhiwen Lu, Sisi Li, Fengfeng Xu, Haishuang Tang, Shijie Zhu, Chuanchuan Wang, Xiaohua Yang, Qinghai Huang   +7 more
wiley   +1 more source

Formulation and in vitro, in vivo evaluation of effervescent floating sustained-release imatinib mesylate tablet. [PDF]

PLoS ONE, 2015
Imatinib mesylate is an antineoplastic agent which has high absorption in the upper part of the gastrointestinal tract (GIT). Conventional imatinib mesylate (Gleevec) tablets produce rapid and relatively high peak blood levels and requires frequent ...
Ali Kadivar, Behnam Kamalidehghan, Hamid Akbari Javar, Ehsan Taghizadeh Davoudi, Nurul Dhania Zaharuddin, Bahareh Sabeti, Lip Yong Chung, Mohamed Ibrahim Noordin   +7 more
doaj   +1 more source

Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells [PDF]

, 2016
Treatment of chronic myelogenous leukemia (CML) with BCR-ABL tyrosine kinase inhibitors (TKI) fails to eliminate leukemia stem cells (LSC). Patients remain at risk for relapse, and additional approaches to deplete CML LSC are needed to enhance the ...
Agarwal, Puneet, Bhatia, Ravi, Campbell, Victoria L., Chu, Su, Gaal, Karl, Holyoake, Tessa L., Hopcroft, Lisa, Jørgensen, Heather G., Lin, Allen, Zhang, Bin   +9 more
core   +1 more source

A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lens

Cancer, Volume 131, Issue 21, 1 November 2025.
ABSTRACT Advances in the prognostication, monitoring, and treatment of both the acute and chronic leukemias have led to drastically improved outcomes over the past 2 decades. With the advent of targeted therapies, including antibodies such as blinatumomab and inotuzumab and small molecule inhibitors, such as the BCR::ABL1 tyrosine kinase inhibitors ...
Hagop M. Kantarjian, Gautam Borthakur, Naval Daver, Courtney DiNardo, Guillermo Garcia‐Manero, Ghayas Issa, Elias Jabbour, Nitin Jain, Tapan Kadia, Sanam Loghavi, Farhad Ravandi, Guilin Tang, Mary Alma Welch, William Wierda   +13 more
wiley   +1 more source

Single-cell epigenomic variability reveals functional cancer heterogeneity. [PDF]

, 2017
BackgroundCell-to-cell heterogeneity is a major driver of cancer evolution, progression, and emergence of drug resistance. Epigenomic variation at the single-cell level can rapidly create cancer heterogeneity but is difficult to detect and assess ...
Buenrostro, Jason D, Chang, Howard Y, Greenleaf, William J, Kathiria, Arwa, Litzenburger, Ulrike M, Sheffield, Nathan C, Shen, Ying, Wu, Beijing   +7 more
core   +2 more sources

The Mechanisms of Imatinib Resistance in Gastrointestinal Stromal Tumours: Theoretical Basis and Therapeutic Aspect

Journal of Cellular and Molecular Medicine, Volume 29, Issue 21, November 2025.
ABSTRACT Imatinib is a small molecule that inhibits receptor tyrosine kinases KIT and platelet‐derived growth factor receptor α (PDGFRA). It was approved by the U.S. Food and Drug Administration (FDA) in 2002 for the treatment of advanced, unresectable gastrointestinal stromal tumours (GISTs). Since then, additional kinase inhibitors targeting multiple
Nuerbiye Abudurexiti, Yidan Lou, Mengqi Wu, Yingchen Huang, Shan Huang, Kaibo Guo, Song Zheng   +6 more
wiley   +1 more source

Yttrium‐90 Selective Internal Radiotherapy for Gastrointestinal Stromal Tumor With Liver Metastasis: A Case Report and Review

Cancer Innovation, Volume 4, Issue 5, October 2025.
Therapeutic protocols are urgent for liver metastases in Gastrointestinal stromal tumors (GIST) patients. This article presents China's first case in GIST liver metastases patients, treating with Yttrium‐90 resin microsphere selective internal radiation therapy, reviews management challenges, and highlights the emerging role of novel therapies to ...
Li Xing, Xiaobin Feng, Lin Zhang, Zheng Mo, Zhuo Yu   +4 more
wiley   +1 more source

Hepatic metastasis with heterologous rhabdomyoblastic differentiation in a patient with gastrointestinal stromal tumor treated with imatinib

Indian Journal of Pathology and Microbiology, 2013
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the intestinal tract. In patients with locally advanced and/or metastatic GIST, the introduction of tyrosine kinase inhibitor, imatinib mesylate, has transformed the ...
Mukul Vij, Susama Patra, Mohamed Rela
doaj   +1 more source

Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases? [PDF]

, 2010
Tissue fibrosis causes organ failure and death in patients with systemic sclerosis (SSc), but clearly effective anti-fibrotic therapies are not available.
Beyer, C, Distler, J H W, Distler, O
core   +1 more source

Efficacy of Eribulin Monotherapy in Patients With Unresectable and/or Metastatic Adenoid Cystic Carcinoma Receiving Platinum‐Based Therapy

Head &Neck, Volume 47, Issue 10, Page 2735-2741, October 2025.
ABSTRACT Background Adenoid cystic carcinoma (ACC) is the second most common and treatment‐resistant salivary gland carcinoma (SGC). Although platinum‐based therapies are effective, the efficacy of eribulin, a microtubule inhibitor with an 18% response rate in a Phase II trial involving recurrent/metastatic SGC, in patients with advanced ACC after ...
Tomomi Sanomachi, Tatsunori Shimoi, Yuki Kojima, Hideaki Takahashi, Motoko Arakaki, Asuka Kawachi, Hitomi Sumiyoshi Okuma, Mai Hoshino, Munehiro Ito, Ayumi Saito, Shosuke Kita, Aiko Maejima, Tadaaki Nishikawa, Kazuki Sudo, Taisuke Mori, Yasuhiro Fujiwara, Kan Yonemori   +16 more
wiley   +1 more source